IMRA News and Press, IMARA Inc. From 06/11/21

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ET BOSTON, June 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq:...

Imara, Inc. (IMRA) Q1 2021 Earnings Conference Call April 11, 2021 08:30 ET Company Participants Michael Gray - Chief Financial Officer & Chief Operating Officer Rahul Ballal - President, Chief Executive Officer & Director Conference Call Participants Yigal Nochomovitz - Citigroup Mat...

Imara (IMRA): Q1 GAAP EPS of -$0.58 beats by $0.25.Cash, cash equivalents and investments were $75.6 million as of March 31, 2021.Press Release For further details see: Imara EPS beats by $0.25

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial Higher dose arms open...

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wil...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.63. So far today approximately 219,000 shares have been exchanged, as compared to an average 30-day volume of 135,000 shares. In the past 52 weeks, shares of IMARA Inc. have traded between the current low of $6.63 and a hig...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.95. Approximately 219,000 shares have changed hands today, as compared to an average 30-day volume of 136,000 shares. There is potential upside of 14.6% for shares of IMARA Inc. based on a current price of $7.01 and an aver...

IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $7.49. This new low was reached on above average trading volume as 219,000 shares traded hands, while the average 30-day volume is approximately 132,000 shares. IMARA Inc. share prices have moved between a 52-week high of $62....

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that applications ...